Treatment of multiple sclerosis and/or rheumatoid arthritis

US9068002B2 · kind B2 · utility

Assignees

• GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS · DE
• Universität Regensburg · DE

Inventors

• Marco Prinz · Glückstadt, DE
• Wolfgang Bruck · Rosdorf, DE
• Alexander Mildner · Lübeck, DE
• Matthias Mack · Regensburg, DE

Key dates

• Filing date: Apr 2, 2007
• Grant date: Jun 30, 2015
• Expiry date: Mar 10, 2028

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/505
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.